Skip to main content
The text for this item is currently unavailable.
PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
- Logan, Joshua E;
- Mostofizadeh, Nikayeh;
- Desai, Amrita J;
- VON Euw, Erika;
- Conklin, Dylan;
- Konkankit, Veerauo;
- Hamidi, Habib;
- Eckardt, Mark;
- Anderson, Lee;
- Chen, Hsiao-Wang;
- Ginther, Charles;
- Taschereau, Eileen;
- Bui, Peter H;
- Christensen, James G;
- Belldegrun, Arie S;
- Slamon, Dennis J;
- Kabbinavar, Fairooz F
- et al.
No data is associated with this publication.
Abstract
Background
PD-0332991 is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, and was evaluated to determine its anti-proliferative effects in 25 renal cell carcinoma (RCC) cell lines.Materials and methods
Half-maximal inhibitory concentrations (IC50) of PD-0332991 were determined with cell line proliferation assays, as were its effects on the cell cycle, apoptosis, and retinoblastoma (RB) phosphorylation. Molecular markers for response prediction, including p16, p15, cyclin D1 (CCND1), cyclin E1 (CCNE1), E2F transcription factor 1 (E2F1), RB, CDK4 and CDK6, were studied using array comparative genomic hybridization (CGH) and gene expression.Results
IC50 values for PD-0332991 ranged from 25.0 nM to 700 nM, and the agent demonstrated G0/G1 cell-cycle arrest, induction of late apoptosis, and blockade of RB phosphorylation. Through genotype and expression data p16, p15 and E2F1 were identified as having significant association between loss and sensitivity to PD-0332991: p16 (p=0.021), p15 (p=0.047), and E2F1 (p=0.041).Conclusion
PD-0332991 has antiproliferative activity in RCC cell lines, and molecular markers predict for sensitivity to this agent.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
The text for this item is currently unavailable.